These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt 2005-003587-34 A phase I-II study: infusion of donor lymphocytes transduced with the suicide gene HSV TK, after transplantation of allogeneic T-depleted stem cells from a haploidentical donor in patients with haemat... not-yet-due
Ongoing 2006-005451-15 NGR006 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by colorectal cancer CRC , previously treated with fluoropyrimidine, oxaliplatin and irinotecan ba... not-yet-due
Ongoing 2006-005696-18 NGR008 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic hepatocellular carcinoma HCC previously treated with no more than one s... not-yet-due
Reported results 2006-005700-14 NGR007 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic small cell lung carcinoma SCLC previously treated with no more than one... 2015-12-03 due-trials
Completed, but no date, and reported results 2006-005993-39 NGR010: A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one s... bad-data
Completed, but no date Terminated 2006-006862-41 TK008: Randomized phase III trial of haploidentical HCT followed by add back of HSV-Tk donor lymphocytes versus haploidentical HCT followed by any T cell repletion strategy in patients with high risk ... bad-data
Completed, but no date, and reported results 2007-000004-33 NGR012: A phase II study of NGR-hTNF administered in combination with doxorubicin every 3 weeks in patients affected by advanced or metastatic ovarian cancer NGR012: studio di fase II relativo alla... bad-data
Ongoing 2007-003668-24 “NGR005: Pilot study of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin-based regimen in patients wit metastatic colorectal cancer” not-yet-due
Completed, but no date, and reported results 2008-002703-20 NGR014: Randomized phase II study of NGR-hTNF in combination with standard chemotherapy versus standard chemotherapy alone in previously untreated patients with advanced non-small cell lung cancer (NS... bad-data
Reported results 2009-012973-37 TK008: Estudio aleatorizado de fase III sobre el trasplante de células hematopoyéticas haploidéntico con o sin una estrategia de apoyo con linfocitos HSV-TK donados, en pacientes con leucemia aguda de... 2019-11-30 due-trials
Reported results 2009-016879-29 NGR015: Randomised double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (M... 2017-12-18 due-trials
Reported results 2010-018851-88 NGR016: Randomized phase II study evaluating two doses of NGR-hTNF administered either as single agent or in combination with doxorubicin in patients with advanced soft-tissue sarcoma (STS) 2016-05-09 due-trials
Reported results 2010-023613-61 NGR018: Randomized phase II study of NGR-hTNF plus an anthracycline versus an anthracycline alone in platinum-resistant ovarian cancer 2016-12-23 due-trials
Completed, but no date, and reported results 2010-023614-31 NGR019: Randomized double-blind phase II study of NGR-hTNF versus placebo as maintenance treatment in advanced malignant pleural mesothelioma (MPM) bad-data
Reported results 2012-005745-20 NGR018: Randomized phase II study of NGR-hTNF plus an anthracycline versus an anthracycline alone in platinum-resistant ovarian cancer NGR018: studio randomizzato di fase II sulla somministrazione... 2016-01-26 due-trials
Exempt, with results Terminated 2018-000813-19 A Phase I-IIa trial to assess the safety and antitumor activity of autologous CD44v6 CAR T-cells in acute myeloid leukemia and multiple myeloma expressing CD44v6. Klinická studie fáze I-IIa k posou... 2021-06-18 not-yet-due